Concepedia

Weiping Zeng

WZ

Statistics

Publications

33

Citations

2.4K

H-Index

21

Active since

2000

Affiliations

Seagen (United States)(Current)

University of Washington

Fred Hutch Cancer Center

University of Rochester

The University of Texas MD Anderson Cancer Center

Weiping Zeng is an author at Seagen (United States) specializing in immunology, life sciences, and medicine.

ORCID

Publications per year

2000–2023

33

Publications

33

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey et al. · Blood · 2013 · 386 citations

, , +13

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

Scott C. Jeffrey, Patrick Burke, Robert P. Lyon et al. · Bioconjugate Chemistry · 2013 · 246 citations

, , +17

<i>Helicobacter</i> Infection Is Required for Inflammation and Colon Cancer in Smad3-Deficient Mice

Lillian Maggio‐Price, Piper M. Treuting, Weiping Zeng et al. · Cancer Research · 2006 · 206 citations · Full text

, , +17

Development of orally active inhibitors of protein and cellular fucosylation

Nicole M. Okeley, Stephen C. Alley, Martha E. Anderson et al. · Proceedings of the National Academy of Sciences · 2013 · 192 citations · Full text

, , +17

<i>Helicobacter</i>-induced inflammatory bowel disease in IL-10- and T cell-deficient mice

Andrew Burich, Robert M. Hershberg, Kim Waggie et al. · American Journal of Physiology-Gastrointestinal and Liver Physiology · 2001 · 182 citations

, , +17

1–5 of 33